Age-related macular degeneration (AMD) poses a significant challenge in ophthalmology, one of the primary causes of irreversible vision loss worldwide. It affects about 8.7% of all blind individuals globally, casting a shadow over the lives of millions, especially the elderly. The prevalence of AMD is expected to rise sharply, with projections indicating that nearly 288 million people will be affected by 2040. 

The impact of AMD goes beyond its clinical aspects, deeply affecting individuals emotionally and economically. Vision problems resulting from AMD not only hinder daily tasks but also contribute to other health issues, such as an increased risk of falls, depression, and greater reliance on long-term care. 

Although current treatments like intravitreal injections are considered standard, they come with challenges like the need for repeated injections and financial burdens. Additionally, alternative therapies, while effective for certain types of AMD, are not universally applicable. 

There’s hope on the horizon with innovations in low-vision aids. Soliddd, an optical technology company, has developed groundbreaking low-vision glasses tailored for macular degeneration. These glasses utilize advanced stereo vision technology to project multiple images onto different parts of the retina, effectively bypassing damaged areas and restoring vision in previously blind spots. Thus, Soliddd is able to create the first real vision correction for macular degeneration. 

A key aspect of Soliddd’s technology is its precise retinal mapping, crucial for accurate gaze tracking and adjusting visual information. This detailed mapping enhances color and brightness on a minute scale, significantly improving the effectiveness of combating macular degeneration. Soliddd’s technology has the potential to not only restore vision but also enhance daily activities such as reading, facial recognition, and navigation, promoting independence and reducing dependence on others. 

In pre-clinical trials, Soliddd’s prototype has shown significant efficacy, with every participant experiencing notable improvement in reading speed. While these do not provide a cure for macular degeneration, they undoubtedly offer hope for those affected by this debilitating condition, in the form of corrective glasses that can eventually be as comfortable to wear as common corrective eyeglasses for myopia. 

 HITLAB will conduct an expert perspective analysis to assess the perceived usability, acceptance, and impact of Soliddd’s technology among Retinologists, low vision specialists and Ophthalmologists. This will help gain insights into Soliddd’s potential fit with provider expectations, needs, and preparedness for anticipated challenges.  

HITLAB is excited to support Soliddd in this initiative toward alleviating the burden of AMD and empowering individuals with visual impairments. So, if you are a Retinologist, low vision specialist or Ophthalmologist willing to contribute towards this project, please write to us at vyadav@hitlab.org.  

As we embark on this journey to revolutionize AMD treatment, the partnership between HITLAB and Soliddd highlights the importance of innovation and collaboration in tackling healthcare challenges. Together, we aim to bring clarity and brightness to the lives of millions affected by macular degeneration.